Recent Pfizer Press Releases

4/6/15 1:00pm EDT
3/30/15 11:06am EDT
Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit

NEW YORK--Pfizer Inc. announced today that Charles Reay Mackay, Ph.D., will join the company as Chief Scientific Officer for Pfizer’s Inflammation and Immunology Research Unit.

3/24/15 10:00am EDT
Pfizer Invites Public To View And Listen To Webcast Of April 28 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2015. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2015 Performance Report, to be issued that morning.

3/23/15 8:00am EDT
Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S.

3/20/15 1:00pm EDT
Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

Detailed Results from OPT Pivotal Studies Along with Integrated Analysis of Safety Data from Psoriasis Global Clinical Development Program Presented at 73rd American Academy of Dermatology (AAD) Annual Meeting

Pfizer Inc.

3/18/15 5:04pm EDT
Results of Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine

Study Showed a Significant Reduction in Vaccine-Type Pneumococcal Community-Acquired Pneumonia in Older Adults Given Prevenar 13

Pfizer Inc.

3/12/15 4:30pm EDT
Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia

Pfizer Inc. (NYSE:PFE) announced today top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica® (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM). The primary endpoint of the study was not achieved as there was not a statistically significant difference between pregabalin and placebo in mean pain score.

3/3/15 8:35am EST
Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

Label Also Updated to Include Data From the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Pfizer Inc.

2/26/15 12:29pm EST
CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

Pfizer Inc. (NYSE: PFE) announced today that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend serogroup B meningococcal vaccination to help protect individuals at increased risk. Specifically, the ACIP voted to recommend serogroup B meningococcal vaccination for persons aged 10 years and older at increased risk for meningococcal disease, including:

2/24/15 8:00am EST
2/20/15 10:30am EST
FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental New Drug Application (sNDA)for RAPAMUNE® (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease in women of childbearing age that is often fatal.

2/13/15 10:27am EST
Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride), extended-release capsules, an abuse-deterrent formulation (ADF) opioid for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ALO-02 is an extended-release oxycodone specifically designed to reduce abuse via the oral, intranasal (i.e., snorting) and intravenous (IV) routes when crushed.

2/12/15 10:35am EST
Safety and Efficacy of ELELYSO® (taliglucerase alfa) for Injection in Pediatric Patients with Type 1 Gaucher Disease in Long-term Outcome Study Presented at the WORLDSymposium 2015

Pfizer Inc. (NYSE: PFE) today announced that researchers presented new data which expand on the existing body of data for ELELYSO (taliglucerase alfa) for injection in pediatric patients with Type 1 Gaucher disease.  These data, which were released today in an oral presentation at the 11th Annual WORLDSymposium in Orlando, include results from a Phase 3, multi-center, extension trial evaluating the long-term efficacy and safety of ELELYSO in pediatric patients with Type 1 Gaucher disease who were treatment-naïve or previously treated with imiglucerase. 

2/9/15 5:27pm EST
Pfizer Commences $5 Billion Accelerated Share Repurchase

Accelerated Share Repurchase Assumed in Pfizer’s 2015 Financial Guidance Issued on January 27, 2015

2/5/15 7:01am EST
Pfizer to Acquire Hospira

  • Transaction will significantly enhance Pfizer’s Global Established Pharmaceutical (GEP) Business
  • Transaction valued at $90 per Hospira share, for a total enterprise value of approximately $17 billion
  • Expected to be immediately accretive upon closing; $0.10-$0.12 accretion expected in first full year after close with additional accretion anticipated thereafter



Pfizer Inc. (NYSE: PFE) and Hospira, Inc. (NYSE: HSP) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of approximately $17 billion. 

2/5/15 6:58am EST
Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Pfizer's Proposed Acquisition of Hospira

Pfizer will hold an analyst and investor call to discuss its proposed acquisition of Hospira at 9:00 AM EST (2:00 PM GMT) today, February 5, 2015. Pfizer will also hold a media call at 10:15 AM EST (3:15 PM GMT) today, February 5, 2015.